Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023

Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023

Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Harpoon Therapeutics Announces Closing of $25 Million Private Placement

Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023

Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022

Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results

Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition

Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors

Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences

Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

Harpoon Therapeutics Expands Leadership Team

Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting

Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer

Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome

Harpoon Therapeutics Announces Leadership Change

Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

Harpoon Therapeutics Provides Pipeline Development Milestones for 2022

Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021

Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition

Harpoon Therapeutics Announces Change to Management Team and Board of Directors

Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences

Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting

Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform

Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting

Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Harpoon Therapeutics to Participate in Truist Securities Life Sciences Summit

Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021

Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of Directors

Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021

Harpoon Therapeutics to Participate in 33rd Annual Roth Conference

Harpoon Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Corporate Update

Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma

Harpoon Therapeutics Announces Closing of Public Offering of Common Stock

Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock

Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock

Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors

Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development Programs

Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020

Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference

Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC™ Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting

Harpoon Therapeutics : Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management

Harpoon Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference

Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance

Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

Harpoon Therapeutics Announces Changes to Board of Directors

Harpoon Therapeutics updates information for its participation in two upcoming virtual conferences

Harpoon Therapeutics to participate in two upcoming virtual conferences

Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

Harpoon Therapeutics to Present Interim Clinical Data For TriTAC® HPN424 At The ASCO20 Virtual Scientific Program

Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Harpoon Therapeutics Doses First Patient With HPN217, a BCMA Targeting TriTAC, For Multiple Myeloma

Harpoon Therapeutics Appoints Two New Members To Its Board Of Directors

Harpoon reports fourth quarter 2019 financial results and provides corporate update

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration

Harpoon reports third quarter results and provides a corporate update

Arix 2019 Capital Markets Day

Harpoon reports second quarter 2019 financial results and provides corporate update

Harpoon Reports first Quarter 2019 financial results and provides corporate update

Harpoon initiates HPN536 Phase 1/2a clinical trial

Harpoon reports full year 2018 financial results and provides corporate update

Harpoon closes initial public offering

Harpoon prices Nasdaq IPO

Update on Harpoon proposed IPO in the United States

Harpoon announces preliminary safety and pharmacology data from its HPN424 Phase 1 trial in prostate cancer

Harpoon announces proposed public offering in the United States

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics